Table I.
| Patient Characteristics | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Age/Sex | CR1 Duration | Prior AML Therapy | Cytogenetics | FLT3 | NPM1 | CEBPA | ELN | Dose Level |
Response | Transplant |
| 67/M | 3mo | Decitabine | 46,XY | ITD+ | Neg | Neg | Int-I | 1 | NR | N |
| 65/M | 16mo | Decitabine, Anti-FLT3 antibody, lenalidomide+ ARAC/Idarubicin, 5+2 | 46,XY,del(2)(p22)[5]/46,sl,t(15;19)(q15;q13.1)[4]/46,sl,t(1;6)(q21;q23)[3]/46,sl,t(7;10)(q11.2;p11.2)[2] | TKD+ | Pos | Neg | Adverse | 1 | NR | N |
| 72/M | 6mo | 7+3, HIDAC, Imatinib | 48,XY,+13,+19[15]/46,XY[5] | Neg | Neg | Neg | Int-II | 1 | NR | N |
| 72/F | PR | Decitabine | 46,XX,del(5)(q22q35)[1]/46,XX[19] | Neg | Neg | Neg | Int-II | 1 | NR | N |
| 76/M | 21mo | Decitabine | 46,XY | Neg | Pos | Neg | Fav | 1 | NR | N |
| 75/F | 9mo | Decitabine | 46,XX | Neg | Neg | Neg | Int-I | 1 | NR | N |
| 72/M | PR | Decitabine | 46,XY | Neg | Neg | Neg | Int-I | 2 | NR | N |
| 64/F | PR | 7+3, 5+2, MEC | 46,XX | ITD+ | Pos | Neg | Int-I | 2 | NR | N |
| 56/F | PR | 5-azacytidine, 7+3, HIDAC | 46,XX,del(9)(q13q22),del(21)(q22)[12]/46,XX,t(5;12)(q31;q22),del(21)(q22) | UK | UK | UK | Adverse | 2 | NR | N |
| 65/M | 9mo; RR | 7+3, IDAC, allograft, lenalidomide | 43,X,-Y,dup(1)(q41q24),−3,del(5)(q13q31),del(6)(q13q23), −7,add(8)(p11.2),ad d(15)(q11.2),psu dic(16:?)(p11.2;?), −17,+mar1,+mar2[1 | Neg | Neg | Neg | Adverse | 2 | NR | N |
| 67/F | 10mo | 7+3, HIDAC, allograft | 46,XX | ITD+ | Pos | Neg | Int-I | 2 | NR | N |
| 34/M | 9mo | ADE, HIDACx2 | 46,XY,inv(16)(p13.1q22)[3]/46,idem,del(7)(q21q36)[9] | Neg | Neg | Neg | Favorable | 3 | CR | Yes |
| 19/M | 2mo | 7+3, HIDACx1 | 46,XY,t(6;9)(p23;q34)[5]/46,sl,del(3)(p13p21)[8]/47,sl,+8 | ITD+ | Neg | Neg | Adverse | 3 | CR | Yes |
| 60/F | PR | 7+3+panobinostat | 46,XX | ITD+ | Neg | Neg | Int-I | 3 | CRi | No |
| 19/F | PR | 7+3 | 46,XX | ITD+ | Neg | Neg | Int-I | 3* | CR | Yes |
| 53/F | PR | 7+3 | 46,XX | Neg | Neg | Neg | Int-I | 3* | CR | Yes |
| 59/M | 17mo | 7+3, HIDACx3 | 46,XY | Neg | Neg | Neg | Int-I | 3* | CR | No |
| 69/F | PR | Vidaza | 41–45,XX,del(5)(q13q33), −7,add(7)(q11.2),add(12)(p11.2),add(13)(q12),psu dic(14;9)(q32;p24)hsr(14)(q32), −17,add(18)(p11.2),+mar[cp8]/44,idem,add(5)( q31)[cp4,one is 4n]/46,XX[13]/ | Neg | Neg | Neg | Adverse | 3* | CR | No |
| 55/M | PR | 7+3, 5+2, Azacytidine+MEC | 44,XY,add(3)(p21),del(5)(q15q33), −7,add(12)(p13), −16, −20,+mar1[1]/45–47,sl, 3,-add(3),hsr(11)(q23),+16,+20,der(21)(11qter->11q23::hsr MLL::11q23->11q13::hsrMLL::11q23->?::21p13->21qter)-mar1,+mar2[cp11]/42–45,sdl1, −9,+add(11)(q23),-hsr(11), −16,-der(21),+mar3[cp3]/44–45,sl,-add(3),+mar2 | Neg | Neg | Neg | Adverse | 3* | NR | No |
| 70/M | 9mo | 7+3, HIDACx2, SGI-110 | 46,XY | Neg | Pos | Neg | Favorable | 3* | CRi/CR | No |
| 23/M | 16mo | 7+3, Autologous Tx | 46,XY,del(9)(q13q22)[13]/46,XY[7] | Neg | Neg | Neg | Int-II | 3A | CR | Yes |
| 27/F | 12mo | 7+3, HIDACx4 | 46,XX | Neg | Pos | Neg | Favorable | 3A | CR | Yes |
| 49/M | 9mo | 7+3, HIDAC, 5-azacytidine+MEC | 46,Y,t(X;6)(p11.2;p25)[11]/46,XY,t(2;3)(p23;q21)[9] | ITD+ | Pos | Pos | Int-II | 3A | NR | No |
| 60/M | 23mo | 7+3,HIDAC | 46,XY | Neg | Neg | Neg | Int-I | 3A | CRi | Yes |
| 31/M | 13mo | 7+3+lenalidomide, HIDACx4 | 46,XY | Neg | Neg | Pos | Fav | 3A | CRi | Yes |
| 57/M | 12mo | 7+3, HIDAC x1 | 46,XY[20] | Neg | Neg | Pos | Fav | 3A | CR | Yes |
| 70/M | PR | Decitabine + Sorafenib | 46,XY[20] | Neg | Neg | Neg | Int-I | 3A | CRi | No |
| 58/M | PR | 7+3 (twice) | Complex | Neg | Neg | Neg | Adverse | 3A | NR | No |
| 48/M | 7mo | 7+3+lenalidomide, HIDAC, allograft | 46,XY | Neg | Neg | Neg | Int-I | 4 | CR | DLI |
| 48/M | PR | 7+3 | 47,XY,+8[13] | ITD+ | Neg | Neg | Int-II | 4 | CR | No |
| 53/F | PR | Decitabine+7+3 | 46,XX,t(2;3)(p25;p11.2) | ITD+ | Pos | Pos | Int-II | 4 | NR | No |
| 59/M | 5mo | 7+3 | 44–47,XY,dic(3;17)(q11.1;q11.2), −5,der(5)inv(5)(q13q34)ins(5;?)(q13;?), −6, −7,+8,ins(16;?)(q12;?),add(17)(p11.2), add(20)(p13),+der(?)t(?;17)(?;q11.2),+r1,+r2,+mar[cp2]/46,XY[18] | Neg | Neg | Neg | Adverse | 4 | CR | Yes |
| 37/F | 5mo | 7+3,HIDACx2, lenalidomide+ARAC+ Idarubicin | 46,XX,inv(16)(p13.1q22)[18]/ | Neg | Neg | Neg | Favorable | 4 | CRi | Yes |
| 62/F | 33mo | 7+3,HIDACx2 | 47,XX,+4[10]/46,XX[10] | Neg | Pos | Pos | Int-II | 4 | CR | Yes |
M=male, F=female, mo=month, CR1= 1st complete remission, AML=acute myeloid leukemia, ELN= European LeukemiaNet, ITD+=internal tandem duplication mutation positive;TKD=tyrosine kinase domain mutation positive, Neg=negative, Int-1=Intermediate-I, Int-II=Intermediate-II, Fav=favorable, NR=No response, CR=Complete remission, CRi=Complete remission with incomplete count recovery, CRi=Complete remission with incomplete platelet or neutrophil recovery, UK=unknown, Pos=positive, HIDAC=high dose cytarabine, allograft-allogeneic stem cell transplant, IDAC=intermediate dose cytarabine, 7+3=daunorubicin and cytarabine, 5+2=daunorubicin and cytarabine, Autologous tx= autologous transplant, ADE=cytarabine, daunorubicin and etoposide, PR=primary refractory